Program
baloxavir
Also written as “Baloxavir Marboxil” and “Baloxavir marboxil”.
Its studies are mostly in Influenza, Human, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 82 open or running | phase 3since Aug 10, 2018 | Aug 10, 2018 | Apr 30, 2027phase 3 · NCT07827599 |
| Shionogi | 20 open or running | phase 3since Oct 27, 2016 | Oct 27, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2016First studies: 2 phase 3 studies in Influenza, HumanNew to ShionogiShionogi · NCT02954354, NCT02949011
- Aug 10, 2018Hoffmann-La Roche's first studies: 2 phase 3 studies in Influenza, HumanNew to Hoffmann-La RocheHoffmann-La Roche · NCT03629184, NCT03653364
- Sep 24, 2018Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT03684044 · 363 enrolled · United States, Argentina, Australia and more
- May 21, 2019No phase study in Healthy VolunteerHoffmann-La Roche · NCT03959332 · 32 enrolled · China
- May 29, 2019Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT03969212 · 4,138 enrolled · United States, Bulgaria, China and more
- Oct 17, 2023Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06094010 · 1,100 planned · United States, Bulgaria, Poland and more
- Jan 9, 2025Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06774859 · 100 enrolled · China
- Sep 15, 2026Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT07827599 · 325 planned · China
Ahead
- Apr 30, 2027Primary completion: phase 3 study in Influenza, HumanHoffmann-La Roche · NCT07827599
- May 11, 2027Primary completion: phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06094010
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Polymerase acidic protein inhibitor; Polymerase acidic protein inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07827599Influenza, Human · China | 3 | Recruiting | Hoffmann-La Roche | Apr 30, 2027 | 325 |
| NCT06774859Influenza, Human · China | 3 | Completed | Hoffmann-La Roche | May 8, 2025 | 100 |
| NCT06094010Influenza, Human · United States, Bulgaria, Poland and more | 3 | Recruiting | Hoffmann-La Roche | May 11, 2027 | 1,100 |
| NCT03969212Influenza, Human · United States, Bulgaria, China and more | 3 | Completed | Hoffmann-La Roche | May 10, 2024 | 4,138 |
| NCT03959332Healthy Volunteer · China | – | Completed | Hoffmann-La Roche | Jul 11, 2019 | 32 |
| NCT03684044Influenza, Human · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Mar 16, 2020 | 363 |
| NCT03653364Influenza, Human · United States, Bulgaria, Costa Rica and more | 3 | Completed | Hoffmann-La Roche | Apr 3, 2023 | 49 |
| NCT03629184Influenza, Human · United States, Costa Rica, Israel and more | 3 | Completed | Hoffmann-La Roche | Apr 3, 2019 | 173 |
| NCT02954354Influenza, Human | 3 | Completed | Shionogi | Apr 4, 2017 | 1,436 |
| NCT02949011Influenza, Human | 3 | Completed | Shionogi | Apr 12, 2018 | 2,184 |
How it is read
Names in the registry
- “Baloxavir Marboxil”, 9 entries
- “Baloxavir marboxil”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.